Zavondemstat sodium
Based on 1 publication(s) in Google Scholar
Zavondemstat sodium (QC8222; TACH 101) sodium is an orally active pan-KDM4 and DHODH inhibitor. Zavondemstat sodium inhibits KDM4A, KDM4B, KDM4C and KDM4D with IC50 values ≤0.080 µM, and exhibits an IC50 of 0.6 nM against human DHODH. Zavondemstat sodium inhibits the KDM4C histone demethylase by competing with the α-ketoglutarate cofactor, and targets DHODH in de novo pyrimidine biosynthesis. Zavondemstat sodium induces apoptosis and S-phase cell cycle arrest, reduces the tumor-initiating cell population, and shows broad antiproliferative activity across multiple cancer cell lines and donor-derived organoids. Zavondemstat sodium can be used for research on colorectal cancer, esophageal squamous cell carcinoma, triple-negative breast cancer and glioblastoma.
For research use only. We do not sell to patients.
- CAS No.: 2908753-07-9
- Formula: C26H28N3NaO3
- Molecular Weight:453.51
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Zavondemstat sodium
More
Biological Activity
Description
|
DHODH 0.6 nM (IC50) |
KDM4A ≤ 0.08 μM (IC50) |
KDM4B ≤ 0.08 μM (IC50) |
KDM4C ≤ 0.08 μM (IC50) |
KDM4D ≤ 0.08 μM (IC50) |
KDM4A 0.52 μM (Ki) |
In Vitro
Zavondemstat (10-0.0005 µM; 7 days) sodium shows broad but selective antiproliferative activity across a 301-cell-line panel, with 209 lines inhibited at IC50 <1 µM[1].
Zavondemstat (144-168 h) sodium is active in SU60, T002C, and SU62 colorectal organoids (IC50 <0.15 µM) and PA0165F pancreatic organoids (IC50 <0.03 µM), but not in several other organoid models[1].
Zavondemstat (5 days) sodium potently inhibits growth of HW1, FPW1, MMK1 and RKI1 glioblastoma stem cells, with GR50 values of 4, 0.4, 7 and 9 nM, respectively[2].
Zavondemstat (100 μM uridine-5 days) sodium growth inhibition in FPW1 glioblastoma cells is strongly rescued by expression of DHODH A58T, supporting DHODH as the functional target[2].
Zavondemstat (60 min preincubation) sodium selectively inhibits KDM4A-D with IC50 ≤ 0.080 µM and has substantially weaker activity against other KDM families[1].
Zavondemstat (24 h) sodium potently inhibits endogenous H3K36me3 demethylation in KYSE-150+KDM4C cells with HTRF IC50 0.0004 µM[1].
Zavondemstat (0.0001-6.7 µM; 24 h) sodium inhibits endogenous H3K36me3 demethylation in KYSE-150+KDM4C cells by immunoblot with IC50 0.085 µM[1].
Zavondemstat (15 min preincubation-45 min reaction) sodium inhibits recombinant KDM4A with an IC50 of 767 nM[2].
Zavondemstat (30 min preincubation-4 h assay) sodium potently inhibits recombinant DHODH with an IC50 of 0.6 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:KYSE-150 cells overexpressing KDM4C
-
Concentration:0.0001, 0.001, 0.003, 0.009, 0.027, 0.082, 0.25, 2.2, and 6.7 µM
-
Incubation Time:24 h
-
Result:Inhibited H3K36me3 demethylation with a mean IC50 of 0.085 µM.
-
Cell Line:301 cancer cell lines from 24 hematologic and solid cancer types
-
Concentration:10-0.0005 µM (10 doses, 1:3 serial dilution)
-
Incubation Time:7 days
-
Result:IC50 values ranged from <500 pM to >10 µM.
Of 301 cell lines, 209 were inhibited with IC50 <1 µM, 89 were insensitive with IC50 ≥10 µM, and 3 had IC50 between 1 and 10 µM.
-
Cell Line:MDA-MB-231 triple-negative breast cancer cells
-
Concentration:0.01 and 0.1 µM
-
Incubation Time:24 h (S-phase data); 48 or 72 h (Methods)
-
Result:Caused S-phase accumulation: 33% and 40% of cells were in S-phase after 0.01 and 0.1 µM, respectively.
Longer exposure resulted in more cells arrested in S-phase.
-
Cell Line:FPW1 and RKI1 glioblastoma cells
-
Concentration:100 μM (uridine)
-
Incubation Time:5 days; 90 min (fluorescence)
-
Result:Exogenous uridine fully reversed growth inhibition in FPW1 and RKI1 glioblastoma cells.
-
Cell Line:FPW1 and FPW1-DHODH A58T glioblastoma cells
-
Concentration:100 μM (uridine)
-
Incubation Time:5 days
-
Result:Expression of DHODH A58T strongly rescued antiproliferative efficacy in FPW1 cells.
Residual weak activity at doses >1 μM was reversed by exogenous uridine.
In Vivo
Zavondemstat (10-23 mg/kg; PO; QD ×7 per week; QOD; 3 on/4 off; 5 on/2 off) sodium inhibits SU60 colorectal cancer xenograft growth in a dose-dependent manner, with 71% tumor growth inhibition at 20 mg/kg PO QD ×7 per week[1].
Zavondemstat (12.5-50 mg/kg; PO; QD; 36 days) sodium inhibits COH70 triple-negative breast cancer xenograft growth dose-dependently, reaching 86% tumor growth inhibition at 40 and 50 mg/kg PO QD ×36[1].
Zavondemstat (5-50 mg/kg; PO; 3 on/4 off; 2 on/5 off) sodium inhibits GXA-3036 gastric cancer xenograft growth, with 69% tumor growth inhibition at 15 mg/kg PO on a 3 on/4 off schedule[1].
Zavondemstat (10-20 mg/kg; PO; QD; 21 days) sodium inhibits KYSE-150 esophageal squamous cell carcinoma xenograft growth dose-dependently, with 84% tumor growth inhibition at 20 mg/kg PO QD ×21[1].
Zavondemstat (5-50 mg/kg; PO; QD 3 on/4 off; BID 3 on/4 off) sodium inhibits OCI-LY19 diffuse large B-cell lymphoma xenograft growth dose-dependently, with 102% tumor growth inhibition and three of eight complete regressions at 25 mg/kg PO BID on 3 on/4 off[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG (nonobese diabetic/severe combined immunodeficiency gamma; female)[1]
-
Dosage:40 mg/kg
-
Administration:PO; QD; 21 days
-
Result:Reduced the proportion of tumorigenic CD44^High EpCAM^+ cells by 2.5-fold and reduced tumor-initiating cell frequency by 4.4-fold.
In limiting dilution, tumor take rates were 7/10 at 1000 cells (mean tumor volume 830 mm3), 5/10 at 500 cells (589 mm3), and 3/10 at 50 cells (209 mm3); TIC frequency was 1 in 643 cells.
-
Animal Model:NSG mice[1]
-
Dosage:5 mg/kg (3 on/4 off); 15 mg/kg (3 on/4 off); 50 mg/kg (3 on/4 off); 22.5 mg/kg (2 on/5 off)
-
Administration:PO; 3 on/4 off; 2 on/5 off
-
Result:On the 3 on/4 off schedule, tumor growth inhibition was 43% at 5 mg/kg, 69% at 15 mg/kg, and 52% at 50 mg/kg.
At 22.5 mg/kg on the 2 on/5 off schedule, TGI was 41%.
-
Animal Model:NSG mice[1]
-
Dosage:10 mg/kg; 15 mg/kg; 20 mg/kg
-
Administration:PO; QD; 21 days
-
Result:Produced dose-dependent tumor growth inhibition of 54% at 10 mg/kg, 76% at 15 mg/kg, and 84% at 20 mg/kg.
-
Animal Model:NSG mice[1]
-
Dosage:5 mg/kg (QD 3 on/4 off); 15 mg/kg (QD 3 on/4 off); 50 mg/kg (QD 3 on/4 off); 25 mg/kg (BID 3 on/4 off)
-
Administration:PO; QD 3 on/4 off; BID 3 on/4 off
-
Result:Produced dose-dependent tumor growth inhibition of 55% at 5 mg/kg, 83% at 15 mg/kg, and 90% at 50 mg/kg on the QD 3 on/4 off schedule.
At 25 mg/kg BID on 3 on/4 off, TGI was 102%, with three of eight complete regressions.
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Flow cytometric DNA-content cell-cycle staining
- Annexin V plus membrane-impermeant dye apoptosis staining
- BrdU Incorporation Assay
- Apoptosis Solutions
- Protocol for Cell Cycle
- Breast Cancer Modeling
- Cell Viability Determination by MTT Colorimetric Assay
Chemical Information
-
CAS No. 2908753-07-9
-
Molecular Weight 453.51
-
Formula C26H28N3NaO3
-
SMILES
O=C(O[Na])C1=CC=NC=C1NC[C@H]2C3=CC=C(N(C4=CC=C(C=C4)C(C)C)C)C=C3OCC2
-
Synonyms
QC8222 sodium; TACH 101 sodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Zavondemstat
- 2908753-07-9
- QC8222
- TACH 101
- QC 8222
- QC-8222
- TACH101
- TACH-101
- Histone Demethylase
- Apoptosis
- Dihydroorotate Dehydrogenase
- DHODH
- KDM4 histone demethylase
- S-phase cell cycle arrest
- alpha-ketoglutarate
- apoptosis
- colorectal cancer
- de novo pyrimidine biosynthesis
- glioblastoma
- tumor-initiating cell
- xenograft
- Inhibitor
- inhibitor
- inhibit